ALSO KNOWN AS LOU GEHRIG’S DISEASE · MOTOR NEURONE DISEASE (MND)
A physician-led, laboratory-verified treatment programme designed to support functional stability, slow disease progression and improve quality of life — tailored to the individual biology, disease stage and clinical profile of each ALS patient.
Request Medical ConsultationAbout the Condition
Amyotrophic Lateral Sclerosis (ALS) — also known as Lou Gehrig’s disease and classified within the broader category of motor neurone disease (MND) — is a progressive neurodegenerative condition that affects the motor neurons controlling voluntary muscle movement.
As motor neurons deteriorate, signals from the brain and spinal cord can no longer reach the muscles. This leads to progressive muscle weakness, paralysis, and — in bulbar-onset ALS — loss of speech and swallowing function.
ALS affects approximately 2–3 people per 100,000 annually. There is no universally effective pharmacological cure. Standard medical management focuses on symptom relief and supportive care — which is precisely where our programme offers a meaningful additional dimension.
Sporadic ALS
The most common form, representing approximately 90–95% of all diagnoses. Occurs without family history and with no identified genetic mutation. Onset is typically between 40 and 70 years of age. Progression rate varies significantly between patients.
Familial ALS (fALS)
Inherited form, accounting for approximately 5–10% of cases. Associated with mutations in SOD1, C9orf72, FUS or TARDBP genes. Often presents earlier than sporadic ALS. Family members may carry the mutation without developing symptoms.
Bulbar-onset ALS
Initial symptoms affect speech, swallowing and tongue mobility. Represents approximately 25% of all ALS cases. Often progresses to affect respiratory function earlier than limb-onset forms. Requires specialised bulbar-focused intervention.
Limb-onset ALS
Initial symptoms affect arm or leg function — weakness, cramping, fine motor difficulty. The most common presentation, representing ~70% of cases. May begin asymmetrically in one limb before spreading. Progression to bulbar involvement varies.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease stage, bulbar and respiratory status, and overall clinical profile.
We do not offer a cure for ALS. Our programme is designed to target the biological mechanisms driving progression — with the clinical objective of stabilising function, slowing decline, and improving daily quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2013 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
257
ALS patients treated since 2013
76%
measurable functional stabilisation on ALSFRS-R at 3–6 months
+1.6 pts
average ALSFRS-R score change at 6 months — vs. expected −3 pts natural decline
71%
sustained functional stability with average 3.5 years of follow-up
82%
showed improvement in one or more measured domains
84%
retained independence in basic activities of daily living (ADL) at 12 months
Motor (fine motor coordination, grip strength, supported standing or transfer)
69%
Bulbar (tongue mobility and articulation, swallowing safety, saliva management)
62%
Respiratory (respiratory endurance, forced vital capacity, delayed dyspnea)
58%
Quality of life (mood and emotional resilience, daily activity tolerance, muscle fatigue reduction, reduced assistance in ADL)
74%
2–6 weeks
Initial functional response
3–6 months
Clinically meaningful change
2–3 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on ALS subtype, baseline ALSFRS-R score, disease duration and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Marc can hold his head up at dinner again. His breathing evened out — the drops we used to get at night just stopped. The progression slowed down and that’s all we were hoping for.”
Patient’s wife
ALS · Belgium
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our ALS programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient’s biological profile, disease stage, and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Particularly important in ALS, where respiratory compromise may make anaesthesia high-risk.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the underlying biology, not just symptoms
Rather than masking symptoms, our protocol targets neuroinflammation, oxidative stress and immune dysregulation — the biological drivers of ALS progression.
Complements existing medication
Our programme is compatible with riluzole and other current standard medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and neuroprotective properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient’s own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in ALS
In ALS, chronic neuroinflammation is one of the primary drivers of motor neuron loss. MSCs directly address this mechanism by suppressing the inflammatory cascade, creating a more stable environment for surviving neurons, and supporting the biological conditions needed for functional preservation.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programmeme is constructed based on your specific diagnosis, disease stage, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current ALSFRS-R status, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, adapted to your current motor function and respiratory status. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors functional status, provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of ALS patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient’s status has changed — including respiratory deterioration — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors motor function, respiratory status and overall well-being
Personalised rehabilitation programmeme
adapted to current functional capacity and ALS stage
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Our approach is based on the principle that biological regeneration requires time, monitoring and adjustment. The period following treatment is as medically important as the treatment itself.
Get Started
If you or someone you love has been diagnosed with ALS, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current stage and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
